Search Results - "LEIGH, Bryan"

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer by ROSEN, Lee S, HURWITZ, Herbert I, THEUER, Charles P, LEIGH, Bryan R, GORDON, Michael S, WONG, Michael K, GOLDMAN, Jonathan, MENDELSON, David S, FIGG, William D, SPENCER, Shawn, ADAMS, Bonne J, ALVAREZ, Delia, SEON, Ben K

“…TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase I, open-label study assessed safety, pharmacokinetics,…”
Get full text

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis by Yang, Yunan, Zhang, Yin, Hong, Hao, Liu, Glenn, Leigh, Bryan R., Cai, Weibo

“…Purpose Angiogenesis is an indispensable process during tumor development. The currently accepted standard method for quantifying tumor angiogenesis is to…”
Get full text

Positron emission tomography imaging of CD105 expression during tumor angiogenesis by Hong, Hao, Yang, Yunan, Zhang, Yin, Engle, Jonathan W., Barnhart, Todd E., Nickles, Robert J., Leigh, Bryan R., Cai, Weibo

“…Purpose Overexpression of CD105 (endoglin) correlates with poor prognosis in many solid tumor types. Tumor microvessel density (MVD) assessed by CD105 staining…”
Get full text

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 by GANDARA, David R, CHANSKY, Kari, CROWLEY, John, LIVINGSTON, Robert, ALBAIN, Kathy S, LEIGH, Bryan R, GASPAR, Laurie E, LARA, Primo N, BURRIS, Howard, GUMERLOCK, Paul, KUEBLER, J. Philip, BEARDEN, James D

“…To test the concept of taxane sequencing in combined-modality therapy, this phase II trial (S9504) evaluated consolidation docetaxel after concurrent…”
Get full text

Swelling-activated Ca2+ channels trigger Ca2+ signals in Merkel cells by Haeberle, Henry, Bryan, Leigh A, Vadakkan, Tegy J, Dickinson, Mary E, Lumpkin, Ellen A

“…Merkel cell-neurite complexes are highly sensitive touch receptors comprising epidermal Merkel cells and sensory afferents. Based on morphological and…”
Get full text

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma by CZUCZMAN, Myron S, THALL, Aron, SWEETENHAM, John, ALKUZWENY, Baha, FINUCANE, Deborah M, LEIGH, Bryan R, WITZIG, Thomas E, VASE, Julie M, YOUNES, Anas, EMMANOUILIDES, Christos, MILLER, Thomas P, MOORE, Joseph O, LEONARD, John P, GORDON, Leo I

“…This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with…”
Get full text

Phase 1 Study of Lumiliximab with Detailed Pharmacokinetic and Pharmacodynamic Measurements in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia by BYRD, John C, O'BRIEN, Susan, MOLINA, Arturo, LEIGH, Bryan, HARRIS, Sarah, FLINN, Lan W, KIPPS, Thomas J, WEISS, Mark, KANTI RAI, LIN, Thomas S, WOODWORTH, James, WYNNE, Dee, REID, Jennifer

“…Purpose: Therapeutic antibodies have improved the outcome for patients with chronic lymphocytic leukemia (CLL). We conducted a phase 1, dose escalation and…”
Get full text

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors by Gordon, Michael S., Rosen, Lee S., Mendelson, David, Ramanathan, Ramesh K., Goldman, Jonathan, Liu, Lili, Xu, Yan, Gerson, Stanton L., Anthony, Stephen P., Figg, William D., Spencer, Shawn, Adams, Bonne J., Theuer, Charles P., Leigh, Bryan R., Weiss, Glen J.

“…Summary Introduction TRC102 potentiates the activity of cancer therapies that induce base excision repair (BER) including antimetabolite and alkylating agents…”
Get full text

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW by Zhang, Yin, Hong, Hao, Severin, Gregory W, Engle, Jonathan W, Yang, Yunan, Goel, Shreya, Nathanson, Alex J, Liu, Glenn, Nickles, Robert J, Leigh, Bryan R, Barnhart, Todd E, Cai, Weibo

“…CD105 (endoglin) is an independent marker for poor prognosis in more than 10 solid tumor types. The goal of this study was to develop a CD105-specific agent…”
Get full text

Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA by Zhang, Yin, Hong, Hao, Engle, Jonathan W, Bean, Jero, Yang, Yunan, Leigh, Bryan R, Barnhart, Todd E, Cai, Weibo

“…Optimizing the in vivo stability of positron emission tomography (PET) tracers is of critical importance to cancer diagnosis. In the case of (64)Cu-labeled…”
Get full text

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma by Wiseman, Gregory A, White, Christine A, Sparks, Richard B, Erwin, William D, Podoloff, Donald A, Lamonica, Dominick, Bartlett, Nancy L, Anthony Parker, J, Dunn, William L, Spies, Stewart M, Belanger, Richard, Witzig, Thomas E, Leigh, Bryan R

“…Radiation dosimetry studies were performed in patients with non-Hodgkin's lymphoma (NHL) treated with 90Y Zevalin™ ( 90yttrium ibritumomab tiuxetan, IDEC-Y2B8)…”
Get full text

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105 by Hong, Hao, Severin, Gregory W., Yang, Yunan, Engle, Jonathan W., Zhang, Yin, Barnhart, Todd E., Liu, Glenn, Leigh, Bryan R., Nickles, Robert J., Cai, Weibo

“…Purpose High tumor microvessel density correlates with a poor prognosis in multiple solid tumor types. The clinical gold standard for assessing microvessel…”
Get full text

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712 by DAVIES, Angela M, CHANSKY, Kari, LAU, Derick H. M, LEIGH, Bryan R, GASPAR, Laurie E, WEISS, Geoffrey R, WOZNIAK, Antoinette J, CROWLEY, John J, GANDARA, David R

“…A previous Southwest Oncology Group (SWOG) study (S9429) demonstrated efficacy and tolerability of concurrent chemoradiotherapy in poor-risk stage III…”
Get full text

Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr and IRDye 800CW by Hong, Hao, Zhang, Yin, Severin, Gregory W, Yang, Yunan, Engle, Jonathan W, Niu, Gang, Nickles, Robert J, Chen, Xiaoyuan, Leigh, Bryan R, Barnhart, Todd E, Cai, Weibo

“…Metastatic breast cancer is incurable. The goal of this study was to develop a positron emission tomography (PET)/near-infrared fluorescent (NIRF) probe for…”
Get full text

Radiation dosimetry results for zevalin radioimmunotherapy of rituximab‐refractory non‐hodgkin lymphoma by Wiseman, Gregory A., Leigh, Bryan, Erwin, William D., Lamonica, Dominick, Kornmehl, Ellen, Spies, Stewart M., Silverman, Daniel H. S., Witzig, Thomas E., Sparks, Richard B., White, Christine A.

“…BACKGROUND Zevalin consists of a murine anti‐CD20 monoclonal antibody (ibritumomab) conjugated to the linker‐chelator tiuxetan, which securely chelates…”
Get full text

Twice-Weekly Paclitaxel and Weekly Carboplatin With Concurrent Thoracic Radiation Followed by Carboplatin/Paclitaxel Consolidation for Stage III Non–Small-Cell Lung Cancer: A California Cancer Consortium Phase II Trial by LAU, Derick, LEIGH, Bryan, GANDARA, David, EDELMAN, Martin, MORGAN, Robert, ISRAEL, Valerie, LARA, Primo, WILDER, Richard, RYU, Janice, DOROSHOW, James

“…Recent studies have suggested the superiority of concurrent chemoradiotherapy and the efficacy of paclitaxel/carboplatin in advanced non-small-cell lung cancer…”
Get full text

Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation for Limited Small-Cell Lung Cancer: Southwest Oncology Group 9713 by EDELMAN, Martin J, CHATISKY, Kari, GASPAR, Laurie E, LEIGH, Bryan, WEISS, Geoffrey R, TAYLOR, Sarah A, CROWLEY, John, LIVINGSTON, Robert, GANDARA, David R

“…Limited small-cell lung cancer (LSCLC) is characterized by a high initial response rate to chemoradiotherapy, but local or systemic relapse occurs in the…”
Get full text

Choosing an optimal radioimmunotherapy dose for clinical response by DeNardo, Sally J., Williams, Lawrence E., Leigh, Bryan R., Wahl, Richard L.

“…Clinical trials have documented the single‐agent efficacy of radioimmunotherapy (RIT) in lymphoma, and several combination therapy studies are now in progress…”
Get full text

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy by Wiseman, Gregory A, Leigh, Bryan R, Dunn, William L, Stabin, Michael G, White, Christine A

“…Zevalin (ibritumomab tiuxetan) radioimmunotherapy is a novel treatment for non-Hodgkin's lymphoma (NHL). The Zevalin regimen includes 5 mCi (111)In-labeled…”
Get more information

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia by Wiseman, Gregory A, Leigh, Bryan R, Erwin, William D, Sparks, Richard B, Podoloff, Donald A, Schilder, Russell J, Bartlett, Nancy L, Spies, Stewart M, Grillo-López, Antonio J, Witzig, Thomas E, White, Christine A

“…This was a 30-patient Phase II trial of reduced-dose (90)Y ibritumomab tiuxetan (Zevalin) RIT for patients with low-grade, follicular, or transformed B-cell…”
Get more information